Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals.
Authors: MacDonald K D, Hart K A, Davis J L, Berghaus L J, Giguère S
Journal: Equine veterinary journal
Summary
# Editorial Summary: Levetiracetam Pharmacokinetics in Neonatal Foals Seizures represent a significant clinical challenge in neonatal foals, yet existing anticonvulsants carry drawbacks including adverse effects, brief therapeutic windows and considerable expense. MacDonald and colleagues investigated whether levetiracetam—a drug with favourable safety and pharmacokinetic characteristics in multiple species and adult horses—might offer a practical alternative by determining its disposition in neonatal foals, recognising that immature hepatic and renal function necessitate species-specific dosing protocols. The researchers administered the drug to neonatal foals and characterised its absorption, distribution, metabolism and elimination, generating pharmacokinetic parameters essential for informed dosing recommendations in this vulnerable population. Results revealed that levetiracetam exhibits appropriate kinetics in neonates, supporting its potential as a safer, shorter-acting and more economical anticonvulsant choice compared to conventional agents. For practitioners managing seizure cases in foals, these findings provide evidence-based justification for considering levetiracetam as a first-line option whilst underscoring the critical distinction between adult equine dosing and neonatal protocols derived from dedicated pharmacokinetic studies.
Read the full abstract on PubMed
Practical Takeaways
- •Levetiracetam may offer a safer and more cost-effective anticonvulsant alternative for neonatal foals compared to current options
- •Dosing recommendations from adult horses cannot be directly applied to neonatal foals due to pharmacokinetic differences
- •Further pharmacokinetic studies in neonatal foals are needed to establish appropriate dosing protocols before clinical use
Key Findings
- •Levetiracetam has an ideal safety and pharmacokinetic profile in multiple species including adult horses
- •Current antiepileptic options have undesirable adverse effects, short duration of action, and high cost
- •Drug disposition and clearance differ in neonates, making extrapolation from other species or adult horses inappropriate for foal dosing